CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC Combined With Other Peptides — Real Peptides

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

41 WORDS

Short answer

Key takeaways

CJC-1295 No DAC combined with other peptides works through dual receptor activation. GHRH receptors and ghrelin receptors operate independently but synergize to produce 2.5–3.5× greater GH release than monotherapy.
Standard research protocols pair 100–200 mcg CJC-1295 No DAC with 100–300 mcg of a GHRP per dose, administered subcutaneously 1–3 times daily.
Ipamorelin is the cleanest GHRP pairing. It selectively activates ghrelin receptors without elevating cortisol or prolactin, making it suitable for sustained multi-week protocols.
GHRP-2 and GHRP-6 produce stronger GH pulses but trigger secondary hormone spikes (cortisol, prolactin, and hunger) that may interfere with specific research objectives.
Timing windows matter. Align peptide administration with natural GH pulse peaks (morning fasted, post-workout, pre-sleep) to amplify endogenous secretion rather than override it.
Reconstituted peptides must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C denature the protein structure irreversibly, rendering the compound inactive.

A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that co-administration of a growth hormone releasing hormone (GHRH) analog with a GHRP produced 3.2-fold greater GH release than either compound alone. The mechanism isn't additive, it's synergistic. CJC-1295 No DAC (also called Modified GRF 1-29) works through the GHRH receptor pathway, while growth hormone releasing peptides like GHRP-2, GHRP-6, and Ipamorelin operate through the ghrelin receptor pathway. Activating both simultaneously creates a pulsatile GH spike that neither compound can achieve independently.

Our team has worked with researchers studying peptide protocols for years. The gap between effective stacking and wasted compounds comes down to timing, receptor mechanics, and dose ratios most protocols ignore entirely.

Can CJC-1295 No DAC be combined with other peptides?

Yes. CJC-1295 No DAC is specifically designed for combination use with growth hormone releasing peptides (GHRPs) like GHRP-2, GHRP-6, and Ipamorelin. The two peptide classes activate separate receptor pathways that synergize to produce 2.5–3.5× greater GH release than monotherapy. Standard research protocols combine 100–200 mcg CJC-1295 No DAC with 100–300 mcg of a GHRP per dose, administered subcutaneously 1–3 times daily.

The featured snippet answers what's possible. What it doesn't cover: the receptor mechanics that make this synergy work, the dose timing windows where the effect compounds or collapses, and the specific peptide pairings that deliver the cleanest results versus those that create redundant signaling. CJC-1295 No DAC combined with other peptides is not about stacking random compounds. It's about pairing agonists that operate through complementary pathways at doses calibrated to avoid receptor desensitization. This article covers the exact receptor pathways involved, the standard stacking protocols used in published research, and the mistakes that negate synergy entirely.

Why CJC-1295 No DAC Requires a GHRP Partner

CJC-1295 No DAC is a GHRH analog. It binds to growth hormone releasing hormone receptors on somatotroph cells in the anterior pituitary, triggering cyclic AMP (cAMP) production and initiating the intracellular cascade that releases stored GH. The critical limitation: GHRH receptor activation alone produces a relatively modest GH pulse unless the somatotroph is already primed by ghrelin receptor activation. Growth hormone releasing peptides (GHRPs). GHRP-2, GHRP-6, Ipamorelin, and Hexarelin. Bind to the ghrelin receptor (growth hormone secretagogue receptor 1a), which sensitizes the somatotroph and removes somatostatin inhibition. When both pathways fire simultaneously, the resulting GH pulse is 2.5–3.5× greater than either compound administered alone.

The reason this matters: GH release is not linear. A single receptor pathway activated in isolation triggers a ceiling effect. The somatotroph can only release so much GH from one signal. Dual-pathway activation lifts that ceiling entirely. A study published in Endocrine Reviews demonstrated that co-administration of a GHRH analog with a GHRP increased peak GH concentrations from 8.2 ng/mL (GHRH alone) to 26.4 ng/mL (combination). A result that cannot be explained by simple additive effects. The synergy is receptor-level, not dose-level.

Our experience guiding research teams through peptide protocols confirms this pattern consistently. Researchers who attempt CJC-1295 No DAC monotherapy report modest results at best. Those who pair it with a GHRP at the correct dose ratio see measurably stronger outcomes within the first two weeks of administration.

Standard Stacking Protocols: Dose Ratios and Timing

The most widely cited research protocols combine 100–200 mcg CJC-1295 No DAC with 100–300 mcg of a GHRP per administration. The exact ratio depends on the specific GHRP selected: Ipamorelin pairs cleanly at 1:1 or 1:1.5 (CJC to GHRP), while GHRP-2 and GHRP-6. Which have stronger ghrelin receptor affinity. Often work better at 1:2 or 1:2.5 ratios. Doses are administered subcutaneously, typically 1–3 times daily depending on research objectives. The half-life of CJC-1295 No DAC is approximately 30 minutes, while GHRPs range from 20–40 minutes. Both compounds clear quickly, making timing precision essential.

Timing windows matter more than most protocols acknowledge. GH pulses are circadian. Natural secretion peaks 60–90 minutes after sleep onset and shows secondary peaks in the early morning and post-exercise. Research protocols align peptide administration with these natural windows to amplify endogenous pulses rather than work against them. The three most common dosing schedules: (1) morning fasted dose upon waking, (2) post-workout dose within 30 minutes of training cessation, and (3) pre-sleep dose 20–30 minutes before bed. Some advanced protocols add a midday dose on non-training days, but frequency beyond three doses daily risks receptor desensitization without proportional benefit.

Reconstitution and storage require precision. Both CJC-1295 No DAC and GHRPs are lyophilized peptides. Store unreconstituted vials at −20°C, reconstitute with bacteriostatic water (not sterile water for multi-dose use), and refrigerate reconstituted solutions at 2–8°C. Once mixed, peptides retain potency for 28 days under proper refrigeration. Any temperature excursion above 8°C degrades the peptide structure irreversibly. At Real Peptides, every batch undergoes HPLC verification to confirm purity above 98%, ensuring researchers work with stable, accurately dosed compounds from the start.

CJC-1295 No DAC Combined With Other Peptides: Best GHRP Pairings

GHRP Option	Receptor Affinity	Typical Dose Range	Synergy Profile	Professional Assessment
Ipamorelin	Selective ghrelin receptor agonist. Minimal cortisol/prolactin elevation	100–300 mcg per dose	Cleanest synergy. No secondary hormone spikes, ideal for sustained protocols	Best first-line pairing for CJC-1295 No DAC. Predictable, minimal side effect profile, smooth GH amplification
GHRP-2	Broad ghrelin receptor agonist. Moderate cortisol/prolactin increase	100–300 mcg per dose	Stronger GH pulse than Ipamorelin, but cortisol elevation may limit long-term use	Effective but requires monitoring. Cortisol spikes can interfere with recovery metrics in multi-week protocols
GHRP-6	Broad ghrelin receptor agonist. Significant hunger stimulation	100–300 mcg per dose	Strong GH release, but pronounced appetite increase complicates fat loss research	Useful in muscle gain or recovery studies where caloric surplus is acceptable. Less suitable for body recomposition research
Hexarelin	Potent ghrelin receptor agonist. Highest cortisol/prolactin response	100–200 mcg per dose	Maximum GH pulse, but desensitization occurs rapidly (5–7 days continuous use)	Reserved for short-term or pulsed protocols only. Not viable for sustained research beyond 2 weeks

The bottom line: Ipamorelin is the most versatile pairing for CJC-1295 No DAC. It delivers consistent synergy without the secondary hormone elevations that complicate GHRP-2 and GHRP-6 protocols. GHRP-6 works well when appetite stimulation aligns with research goals. Muscle gain studies, recovery from injury, or metabolic research where caloric intake isn't restricted. Hexarelin produces the strongest single-dose GH spike but loses effectiveness too quickly for multi-week studies. Our FAT Loss Stack includes pairing options calibrated for clean synergy without cortisol interference.

What If: CJC-1295 No DAC Stacking Scenarios

What If You Combine CJC-1295 No DAC With Multiple GHRPs Simultaneously?

Avoid stacking multiple GHRPs in the same administration. Receptor saturation occurs at the ghrelin receptor, and adding a second GHRP doesn't amplify the signal proportionally. The ghrelin receptor pathway has a functional ceiling. Once Ipamorelin or GHRP-2 saturates available receptors, adding GHRP-6 to the same dose creates redundant signaling without additional benefit. Multi-GHRP stacks are common in unverified internet protocols but lack supporting evidence in published research. Stick to one GHRP per dose paired with CJC-1295 No DAC.

What If You Add MK-677 to a CJC-1295 No DAC and GHRP Protocol?

MK-677 (Ibutamoren) is an oral ghrelin receptor agonist with a 24-hour half-life. Adding it to a pulsatile CJC/GHRP protocol creates continuous ghrelin receptor activation that may blunt the acute synergy the stack depends on. Pulsatile GH release is more anabolic and less insulin-resistant than sustained baseline elevation. Combining pulsatile peptides with a continuous oral secretagogue flattens the peaks that drive the desired response. If both are used, administer MK-677 separately (evening dose for sleep/recovery benefits) and keep CJC/GHRP doses at least 12 hours apart. Our Sleep Stack includes MK-677 as a standalone evening protocol rather than layered with injectable peptides.

What If You Experience Injection Site Reactions When Combining Peptides?

Rotate injection sites across abdomen, thighs, and deltoids. Injecting the same site repeatedly causes localized inflammation and lipohypertrophy (fat accumulation under the skin). Use a fresh needle for every injection, never reuse, and ensure bacteriostatic water was used for reconstitution (sterile water for multi-dose vials promotes bacterial growth). If reactions persist despite rotation, the issue may be peptide purity or an excipient sensitivity. Switch suppliers and verify HPLC testing results. All peptides at Real Peptides include third-party purity verification to minimize contamination risk.

The Direct Truth About CJC-1295 No DAC Stacking

Here's the honest answer: most peptide stacks marketed online are nonsense. Combining five or six peptides in a single protocol doesn't produce five or six times the result. It produces receptor desensitization, unpredictable side effects, and wasted compounds. CJC-1295 No DAC combined with other peptides works because it activates two complementary pathways with distinct mechanisms. GHRH and ghrelin receptors operate independently but amplify each other when fired together. That's it. Adding IGF-1 LR3, BPC-157, or Thymosin Beta-4 to the same injection doesn't enhance GH release. Those peptides work through entirely separate pathways and should be dosed independently if used at all.

The evidence is clear: dual-pathway GH secretagogue stacks (CJC + GHRP) are the only peptide combination with reproducible synergy documented in peer-reviewed endocrinology research. Everything beyond that is speculation dressed up as advanced protocol design. Stick to the two-compound stack, dose it correctly, and time it with natural GH pulse windows. That's the protocol that works.

Avoiding the Most Common Stacking Mistakes

The biggest mistake researchers make when combining CJC-1295 No DAC with other peptides isn't dose selection. It's reconstitution order. Mixing both peptides in the same vial before administration introduces contamination risk and makes dose precision nearly impossible. Reconstitute each peptide separately in its own vial, draw the required dose of each into the same syringe sequentially (CJC first, then GHRP), and administer the combined solution immediately. Never pre-mix peptides days in advance. Stability degrades once compounds interact in solution.

Another common error: dosing too frequently. Three doses daily is the ceiling for sustained protocols. Anything beyond that risks receptor downregulation without proportional benefit. The anterior pituitary adapts to chronic stimulation by reducing GHRH and ghrelin receptor density, a process that takes 10–14 days of continuous high-frequency dosing. Researchers pushing four or five doses daily often report diminishing returns by week three. The same outcome you'd expect from receptor desensitization.

Storage failures negate synergy entirely. A single overnight temperature excursion (leaving reconstituted peptides out of the refrigerator) denatures the protein structure enough to render the compound biologically inactive. The degraded peptide may look identical to fresh solution, but HPLC analysis would show fragmented amino acid chains incapable of receptor binding. If you're uncertain whether a vial was stored correctly, discard it and reconstitute a fresh dose. Using degraded peptides wastes time and skews research data.

CJC-1295 No DAC combined with other peptides delivers the receptor synergy peptide research depends on. But only when protocols respect the underlying biology. Dual-pathway activation works. Multi-peptide chaos doesn't. The researchers who see consistent results are the ones who keep protocols simple, dose timing precise, and storage conditions uncompromising. That's the standard we hold at Real Peptides. Research-grade purity, exact amino-acid sequencing, and HPLC verification on every batch shipped.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — CJC-1295 No DAC and Ipamorelin are the most commonly paired peptides in research protocols because they activate complementary pathways (GHRH and ghrelin receptors) that synergize to produce 2.5–3.5× greater GH release than either compound alone. Standard protocols combine 100–200 mcg CJC-1295 No DAC with 100–300 mcg Ipamorelin per dose, administered subcutaneously 1–3 times daily. Ipamorelin is the preferred GHRP pairing because it selectively activates ghrelin receptors without elevating cortisol or prolactin, making it suitable for sustained multi-week studies.

The most effective dose ratios range from 1:1 to 1:2.5 (CJC to GHRP), depending on the specific GHRP selected. Ipamorelin pairs cleanly at 1:1 or 1:1.5 ratios (e.g., 100 mcg CJC with 100–150 mcg Ipamorelin), while GHRP-2 and GHRP-6 — which have stronger ghrelin receptor affinity — often work better at 1:2 or 1:2.5 ratios (e.g., 100 mcg CJC with 200–250 mcg GHRP). Higher GHRP doses amplify the synergy but also increase the risk of secondary hormone elevation (cortisol, prolactin) with GHRP-2 and GHRP-6.

Most research protocols dose CJC-1295 No DAC and GHRP combinations 1–3 times daily, with three doses being the practical ceiling before receptor desensitization risk increases. Common schedules include morning fasted dosing upon waking, post-workout dosing within 30 minutes of training, and pre-sleep dosing 20–30 minutes before bed. The half-life of both CJC-1295 No DAC and GHRPs is 20–40 minutes, so pulsatile dosing aligned with natural GH secretion windows produces stronger results than continuous or high-frequency administration.

No — reconstitute each peptide separately in its own vial, then draw the required dose of each into the same syringe sequentially before administration. Pre-mixing peptides in the same vial days in advance introduces contamination risk and reduces stability — once compounds interact in solution, degradation accelerates. The correct sequence: reconstitute CJC-1295 No DAC in one vial with bacteriostatic water, reconstitute the GHRP in a separate vial, draw CJC dose into syringe first, then draw GHRP dose into the same syringe, and inject immediately.

GHRP-2 and GHRP-6 elevate cortisol and prolactin moderately in addition to stimulating GH release — cortisol spikes of 15–30% above baseline are common, and prolactin can increase transiently in the 60–90 minutes post-injection. GHRP-6 also triggers pronounced hunger stimulation (ghrelin is the 'hunger hormone'), which may interfere with fat loss or caloric restriction research. Ipamorelin avoids both issues — it selectively activates ghrelin receptors without cortisol or prolactin elevation, making it the preferred pairing for sustained protocols where secondary hormone effects would confound results.

Yes — fasted administration produces stronger GH pulses because elevated blood glucose and insulin suppress growth hormone secretion. Research protocols typically require at least 2–3 hours fasted before dosing and 30–60 minutes fasted after dosing before consuming calories. Morning fasted doses upon waking and pre-sleep doses (after dinner has been fully digested) align naturally with fasted windows. Post-workout doses are also typically administered before post-training nutrition, maintaining the fasted state during the GH pulse window.

Acute GH elevation occurs within 15–30 minutes of administration and peaks at 45–60 minutes post-injection — this is measurable via serum GH testing. Observable physiological effects (improved recovery, body composition changes, sleep quality) typically become apparent within 2–4 weeks of consistent dosing at therapeutic ranges. The timeline depends on research objectives: recovery markers improve faster than body composition metrics, and both require sustained administration (6–12 weeks minimum) to reach meaningful endpoints.

Yes, but they serve entirely separate functions and should not be considered part of the same 'stack' from a receptor synergy perspective. CJC-1295 No DAC and GHRPs stimulate growth hormone release through pituitary receptor activation. BPC-157 and TB-500 (Thymosin Beta-4) are tissue repair peptides that work through distinct pathways — BPC-157 upregulates growth factor expression locally, and TB-500 promotes actin polymerization and cell migration. Combining them doesn't create synergy the way CJC + GHRP does — they're simply administered concurrently for different research endpoints.

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6–8 days due to albumin binding, creating sustained baseline GH elevation rather than pulsatile spikes. CJC-1295 No DAC (Modified GRF 1-29) has a 30-minute half-life and produces sharp, short-duration GH pulses when paired with a GHRP. Pulsatile release is more anabolic and metabolically favorable than sustained baseline elevation — research protocols favor CJC-1295 No DAC for this reason. CJC with DAC is dosed once or twice weekly; CJC No DAC is dosed 1–3 times daily.

Refrigerate reconstituted peptide solutions at 2–8°C immediately after mixing and use within 28 days for maximum potency retention. Store unreconstituted lyophilized peptides at −20°C until ready for use. Any temperature excursion above 8°C degrades the peptide structure — leaving reconstituted vials out overnight or storing them at room temperature denatures the protein irreversibly, rendering the compound biologically inactive. Once a vial has been compromised by improper storage, discard it and reconstitute a fresh dose.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA